Hepatology Unit, Digestive Disease Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Department of Gastroenterology and Hepatology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Semin Liver Dis. 2024 Aug;44(3):356-368. doi: 10.1055/a-2378-8942. Epub 2024 Aug 2.
Ammonia is a product of amino acid metabolism that accumulates in the blood of patients with cirrhosis and plays a pivotal role in the pathogenesis of hepatic encephalopathy (HE). Despite being one of the main drivers of brain dysfunction, for many years international societies stated that increased blood ammonia does not add any diagnostic, staging, or prognostic value for HE in patients with cirrhosis. Nonetheless, in the last decades, evidence is emerging that supports the utility of ammonia for risk stratification, but its role in guiding HE diagnosis, staging, and treatment is unclear and there is equipoise in its use in clinical practice. This review provides the latest evidence on the value of ammonia as a biomarker in patients with cirrhosis. Although correct measurement of ammonia requires disciplined sample collection, it provides extremely useful clinical guidance for the diagnosis of HE, offers prognostic information, and it defines a therapeutic target.
氨是氨基酸代谢的产物,在肝硬化患者的血液中积累,在肝性脑病 (HE) 的发病机制中起着关键作用。尽管氨是大脑功能障碍的主要驱动因素之一,但多年来,国际社会一直认为肝硬化患者血液中氨的增加对 HE 的诊断、分期或预后没有任何价值。然而,在过去的几十年中,有证据表明氨对风险分层有用,但氨在指导 HE 诊断、分期和治疗中的作用尚不清楚,其在临床实践中的应用也存在争议。这篇综述提供了关于氨作为肝硬化患者生物标志物价值的最新证据。虽然氨的正确测量需要严格的样本采集,但它为 HE 的诊断提供了极其有用的临床指导,提供了预后信息,并定义了治疗目标。